: Large firms like Eli Lilly and Novartis are racing to replace revenue from older drugs that are nearing patent expiration.
: Analysts maintain an Overweight rating , forecasting significant upside potential. If you're looking for more info, are you interested in: Specific types of cancer treatments (like CAR-T or ADCs)? Financial analysis of these stocks? Clinical trial details for these new acquisitions? buy cancer
: Rated as a Strong Buy by Piper Sandler for its work in overcoming treatment resistance. : Large firms like Eli Lilly and Novartis
Major pharmaceutical companies have been on a massive spending spree in 2025 and 2026, acquiring innovative biotech firms to bolster their cancer-treatment pipelines. Financial analysis of these stocks
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more